These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 10337378

  • 1. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
    Bookman MA.
    Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
    [Abstract] [Full Text] [Related]

  • 2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 3. New options for the treatment of advanced ovarian cancer.
    Dunton CJ.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [Abstract] [Full Text] [Related]

  • 4. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Feb; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 5. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J.
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [Abstract] [Full Text] [Related]

  • 6. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF.
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [Abstract] [Full Text] [Related]

  • 7. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 8. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
    du Bois A, Lück HJ, Meerpohl HG.
    Zentralbl Gynakol; 1997 Jan; 119(7):299-323. PubMed ID: 9340970
    [Abstract] [Full Text] [Related]

  • 9. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
    Lin H, Changchien CC.
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
    [Abstract] [Full Text] [Related]

  • 10. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
    Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E.
    Oncology; 2007 Dec; 73(3-4):177-84. PubMed ID: 18418010
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 12. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
    Lehoczky O, Bagaméri A, Lehoczky G, Pulay T.
    Orv Hetil; 2002 Apr 21; 143(16):825-8. PubMed ID: 12053883
    [Abstract] [Full Text] [Related]

  • 13. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Marforio G, Ballardini M, Lombardi AV, Sorio R, Tumolo S, Costa B, Magni G, Perrone F, Favalli G, SOCRATES and MITO investigators.
    Oncology; 2006 Apr 21; 71(5-6):320-6. PubMed ID: 17878745
    [Abstract] [Full Text] [Related]

  • 14. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P, Nolte S, Shahin MS.
    Gynecol Oncol; 2002 May 21; 85(2):278-84. PubMed ID: 11972388
    [Abstract] [Full Text] [Related]

  • 15. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
    Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W, Sehouli J, North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer.
    Cancer Chemother Pharmacol; 2008 Aug 21; 62(3):393-400. PubMed ID: 17922272
    [Abstract] [Full Text] [Related]

  • 16. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
    Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators.
    Gynecol Oncol; 2004 Oct 21; 95(1):1-8. PubMed ID: 15385103
    [Abstract] [Full Text] [Related]

  • 17. Treatment options in patients with recurrent ovarian cancer.
    Gadducci A, Conte P, Cianci C, Negri S, Genazzani AR.
    Anticancer Res; 2001 Oct 21; 21(5):3557-64. PubMed ID: 11848523
    [Abstract] [Full Text] [Related]

  • 18. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K.
    Gynecol Oncol; 2000 Apr 21; 77(1):112-5. PubMed ID: 10739699
    [Abstract] [Full Text] [Related]

  • 19. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
    Qian XL, Peng ZL, Liu SL.
    Ai Zheng; 2003 Dec 21; 22(12):1352-4. PubMed ID: 14693068
    [Abstract] [Full Text] [Related]

  • 20. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec 21; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.